ATE482716T1 - Zusammensetzungen basierend auf apo2-ligand/ trail und ihre verwendung - Google Patents

Zusammensetzungen basierend auf apo2-ligand/ trail und ihre verwendung

Info

Publication number
ATE482716T1
ATE482716T1 AT02784443T AT02784443T ATE482716T1 AT E482716 T1 ATE482716 T1 AT E482716T1 AT 02784443 T AT02784443 T AT 02784443T AT 02784443 T AT02784443 T AT 02784443T AT E482716 T1 ATE482716 T1 AT E482716T1
Authority
AT
Austria
Prior art keywords
trail
formulations
compositions based
apo2 ligand
methods
Prior art date
Application number
AT02784443T
Other languages
English (en)
Inventor
Heather Flores
Tanya Lin
Roger Pai
Timothy Matthews
Zahra Shahrokh
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE482716T1 publication Critical patent/ATE482716T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT02784443T 2001-11-13 2002-11-12 Zusammensetzungen basierend auf apo2-ligand/ trail und ihre verwendung ATE482716T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33824901P 2001-11-13 2001-11-13
PCT/US2002/036251 WO2003042344A2 (en) 2001-11-13 2002-11-12 Apo2 ligand/trail formulations

Publications (1)

Publication Number Publication Date
ATE482716T1 true ATE482716T1 (de) 2010-10-15

Family

ID=23324037

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02784443T ATE482716T1 (de) 2001-11-13 2002-11-12 Zusammensetzungen basierend auf apo2-ligand/ trail und ihre verwendung

Country Status (11)

Country Link
US (3) US7741282B2 (de)
EP (3) EP2322165A1 (de)
JP (2) JP2005521640A (de)
AT (1) ATE482716T1 (de)
CA (1) CA2466054C (de)
DE (1) DE60237841D1 (de)
DK (1) DK1450847T3 (de)
ES (1) ES2351786T3 (de)
IL (3) IL161812A0 (de)
PT (1) PT1450847E (de)
WO (1) WO2003042344A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5118796B2 (ja) * 1999-06-28 2013-01-16 ジェネンテック， インコーポレイテッド 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
KR20050090430A (ko) 2002-12-31 2005-09-13 알투스 파마슈티컬스 인코포레이티드 인간 성장 호르몬 결정 및 이것의 제조 방법
NZ554885A (en) * 2002-12-31 2009-07-31 Altus Pharmaceuticals Inc Complexes of hgh crystals and protamine polymers
US20060019234A1 (en) * 2004-07-22 2006-01-26 Shanbrom Technologies, Llc Modern blood banking employing improved cell preservation composition
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20090155247A1 (en) * 2005-02-18 2009-06-18 Ashkenazi Avi J Methods of Using Death Receptor Agonists and EGFR Inhibitors
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
AU2006256802A1 (en) * 2005-06-06 2006-12-14 Novo Nordisk A/S Stabilised IL-21 compositions
AU2006279578A1 (en) * 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensivity to Apo2L/TRAIL by testing for GalNac-T14 expression in cells/tissues
EA014232B1 (ru) * 2005-12-20 2010-10-29 Бристол-Маерс Сквибб Компани Стабильные белковые препараты
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
WO2009022154A2 (en) 2007-08-15 2009-02-19 Circassia Limited Peptide with multiple epitopes
EP2591804A3 (de) 2007-09-24 2014-04-16 Bar-Ilan University Mit Magnetmetalloxid beschichtete Polymer-Nanopartikel und Verwendungen dafür
EP2111871A1 (de) * 2008-04-26 2009-10-28 Sandoz AG Stabilisierte Flüssigformulierung
DK2350271T3 (en) 2008-11-20 2016-04-04 Biogen Ma Inc ARGININ INACTIVATION OF ENVIRONMENT VIRA
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
DE102008064553B4 (de) * 2008-12-22 2015-05-13 Technische Universität Dresden Verfahren zum Nachweis und/oder zur Identifizierung hormonell wirksamer Substanzen
US8293101B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
SG181496A1 (en) 2009-12-18 2012-07-30 Csl Ltd Method of purifying polypeptides
PH12012502140A1 (en) * 2010-04-27 2013-02-04 Scil Tech Gmbh Stable mia/cd-rap formulation
MX2012012743A (es) * 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
MX2013012716A (es) 2011-05-03 2014-03-21 Genentech Inc Agentes de disociacion vascular y sus usos.
RU2014150071A (ru) * 2012-05-11 2016-07-10 Новартис Аг Способы кристаллизации для очистки моноклональных антител
CA2913115A1 (en) * 2013-06-09 2014-12-18 Efranat Ltd. Compositions comprising gc-macrophage activating factor and uses thereof
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
UY38238A (es) * 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
EA202191385A1 (ru) * 2018-12-21 2021-11-15 Икнос Сайенсис С.А. Способы осветления культур клеток

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS5829958B2 (ja) * 1977-03-07 1983-06-25 工業技術院長 タンパク質結晶の形成方法
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS60126084A (ja) * 1983-12-13 1985-07-05 Toyo Jozo Co Ltd グリセロリン酸オキシダーゼの安定化法
JPS62283932A (ja) 1986-05-29 1987-12-09 Green Cross Corp:The 組織プラスミノ−ゲンアクチベ−タの乾燥製剤
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JP2602850B2 (ja) * 1987-10-27 1997-04-23 富士通株式会社 単結晶作製方法
WO1989005859A1 (en) 1987-12-21 1989-06-29 The Upjohn Company Agrobacterium mediated transformation of germinating plant seeds
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
CH682806A5 (de) 1992-02-21 1993-11-30 Medimpex Ets Injektionsgerät.
JP3007785B2 (ja) * 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
ES2253753T3 (es) * 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
PT939804E (pt) 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
AU713471C (en) 1996-12-23 2002-04-18 Immunex Corporation Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily
DK1012274T4 (da) 1997-01-28 2011-07-25 Human Genome Sciences Inc Dødsdomæneholdig receptor-4 (DR4: dødsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
US7803615B1 (en) 1997-03-17 2010-09-28 Human Genome Sciences, Inc. Death domain containing receptor 5
US6140475A (en) * 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
HU230547B1 (hu) 1997-04-16 2016-11-28 Amgen Inc. Osteoprotegerin-kötő fehérjék és receptorok
CA2287085A1 (en) 1997-04-16 1998-10-22 Millennium Pharmaceuticals, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
ATE516354T1 (de) 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
EP2083079A1 (de) 1997-06-18 2009-07-29 Genentech, Inc. Apo-2DcR
CA2294729C (en) 1997-07-02 2003-05-06 The Procter & Gamble Company Suspension for adding a controlled amount of ingredient to a food product
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
WO1999006673A1 (en) 1997-07-30 1999-02-11 Eg & G Sealol, Inc. Improved brush seal and method of making same
CA2301202A1 (en) 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
DE69841176D1 (en) 1997-08-26 2009-11-05 Genentech Inc Rtd receptor
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
ES2316182T3 (es) 1998-01-15 2009-04-01 Genentech, Inc. Ligando apo-2.
JP4194681B2 (ja) * 1998-01-20 2008-12-10 太陽化学株式会社 可溶性γ−リベチン複合体の製造法
ES2308836T3 (es) 1998-03-27 2008-12-01 Genentech, Inc. Sinergia de los anticuerpos anti-her-2 y de los ligands para l'apo-2.
GB2349636A (en) 1998-09-17 2000-11-08 Adv Liquid Packaging Corp Resealable can
FR2783596B1 (fr) 1998-09-23 2001-03-09 Eurokera Ensemble prefabrique destine a la realisation de tables de cuisson
CA2375149A1 (en) 1999-06-09 2000-12-14 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
JP5118796B2 (ja) 1999-06-28 2013-01-16 ジェネンテック， インコーポレイテッド 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法
AUPQ312699A0 (en) 1999-09-28 1999-10-21 Electrical Moulded Components Pacific Pty Ltd Electrical reticulation apparatus
AU766984B2 (en) 1999-09-30 2003-10-30 Trustees Of The University Of Pennsylvania, The Trail: an inhibitor of autoimmune inflammation and cell cycle progression
HUP0203133A3 (en) 1999-10-04 2005-07-28 Chiron Corp Emeryville Stabilized liquid polypeptide-containing pharmaceutical compositions
DK1129720T3 (da) * 2000-02-29 2004-09-27 Pfizer Prod Inc Stabiliseret granulocyt-kolonistimulerende faktor
EP1303293B1 (de) 2000-07-27 2008-12-03 Genentech, Inc. Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
JP2005508162A (ja) * 2001-10-02 2005-03-31 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド変異体とその使用法
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations

Also Published As

Publication number Publication date
WO2003042344A2 (en) 2003-05-22
EP1450847A2 (de) 2004-09-01
US7741282B2 (en) 2010-06-22
JP2009108040A (ja) 2009-05-21
ES2351786T3 (es) 2011-02-10
DE60237841D1 (de) 2010-11-11
US20050080006A1 (en) 2005-04-14
US20050020498A1 (en) 2005-01-27
EP2332531B1 (de) 2019-07-10
WO2003042344A3 (en) 2003-11-27
US20110269947A1 (en) 2011-11-03
CA2466054A1 (en) 2003-05-22
EP1450847A4 (de) 2007-08-29
PT1450847E (pt) 2011-01-05
IL161812A0 (en) 2005-11-20
EP1450847B1 (de) 2010-09-29
EP2332531A1 (de) 2011-06-15
EP2322165A1 (de) 2011-05-18
DK1450847T3 (da) 2010-12-13
US8470969B2 (en) 2013-06-25
CA2466054C (en) 2012-01-03
JP2005521640A (ja) 2005-07-21
JP5042959B2 (ja) 2012-10-03
IL197705A0 (en) 2009-12-24
IL161812A (en) 2013-02-28

Similar Documents

Publication Publication Date Title
ATE482716T1 (de) Zusammensetzungen basierend auf apo2-ligand/ trail und ihre verwendung
ATE469892T1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
ATE517089T1 (de) Trifluormethylsubstituierte spirocyclische ketoenole und ihre verwendung als schädlingsbekämpfungsmittel und herbizide
ECSP045255A (es) Cumarinas utiles como biomarcadores
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
CA2492096A1 (en) Cis-alkoxy-substituted spirocyclic 1-h-pyrrolidine-2,4-dione derivatives serving as pesticides
BRPI0412402A (pt) polipeptìdeos de amilase termoestáveis, ácidos nucléicos codificando esses polipeptìdeos e seus usos
DE602004029503D1 (de) Plasmid der 2-mikron-familie und verwendung davon
ATE466012T1 (de) Pyrazolo 3,4-b pyridinverbindungen und ihre verwendung als phosphodiesterase inhibitoren
MXPA03008754A (es) Derivados de piridina fundidos para utilizarse como agonistas receptores vaniloide para tratar dolor.
ATE429450T1 (de) Chimärische dr4 antikörper und ihre verwendung
DE60142828D1 (de) Modifizierte oligonukleotide zur unterscheidung von fehlpaarungen
DK1083903T3 (da) Brobundne indenopyrrolocarbazoler
TW200510435A (en) Platinum complexes
DK1419163T5 (da) Tricykliske imidazopyridiner
WO2005009951A3 (en) Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
WO2005035537A3 (en) Substituted tricyclic heterocycles and their uses
MXPA06000038A (es) Pirimidinas 2-sustituidas.
ATE240326T1 (de) Pyrrolo-(3,2-b)pyridine und ihre verwendung als 5-ht1f agonisten
TW200716130A (en) Purified form of tanaproget
ATE389014T1 (de) Phosphorylierte glyoxalase i und deren verwendung
PL375350A1 (en) Indol derivatives and their use as 5-ht ligands
GB0401187D0 (en) Organic compounds
ATE338045T1 (de) Substituierte pyrido(1,2-a)pyrimidine und ihre verwendung als nos-inhibitoren
ATE417040T1 (de) Nitratester von phenylaminothiophen- essigsäurederivaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1450847

Country of ref document: EP